French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN) guidelines for the management of patients with partially responsive depression and treatment-resistant depression: Update 2024.
L'Encéphale. 2024-02-01; :
DOI: 10.1016/j.encep.2023.11.029
Lire sur PubMed
1. Encephale. 2024 Feb 17:S0013-7006(24)00019-8. doi:
10.1016/j.encep.2023.11.029. Online ahead of print.
French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN)
guidelines for the management of patients with partially responsive depression
and treatment-resistant depression: Update 2024.
Yrondi A(1), Javelot H(2), Nobile B(3), Boudieu L(4), Aouizerate B(5), Llorca
PM(6), Charpeaud T(7), Bennabi D(8), Lefrere A(9), Samalin L(10).
Author information:
(1)French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN),
Saint-Germain-en-Laye, France; Fondation FondaMental, Créteil, France; Inserm,
UPS, ToNIC, service de psychiatrie et psychologie médicale, Centre expert
dépression résistante, Toulouse NeuroImaging Center, université de Toulouse, CHU
de Toulouse, Toulouse, France.
(2)French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN),
Saint-Germain-en-Laye, France; EPSAN, Centre de Ressources et d’Expertise en
PsychoPharmacologie du Grand’Est (CREPP GE), Brumath, France; UR7296,
laboratoire de pharmacologie, faculté de médecine de Strasbourg, Centre de
recherche en biomédecine de Strasbourg (CRBS), Strasbourg, France.
(3)French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN),
Saint-Germain-en-Laye, France; Fondation FondaMental, Créteil, France;
Department of Emergency Psychiatry and Acute Care, CHU de Montpellier,
Montpellier, France; Inserm, CNRS, IGF, University of Montpellier, Montpellier,
France.
(4)French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN),
Saint-Germain-en-Laye, France; Department of Psychiatry, CHU of
Clermont-Ferrand, University of Clermont Auvergne, CNRS, Clermont Auvergne INP,
Institut Pascal (UMR 6602), Clermont-Ferrand, France.
(5)French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN),
Saint-Germain-en-Laye, France; Fondation FondaMental, Créteil, France; Centre
hospitalier Charles-Perrens, université de Bordeaux, Bordeaux, France; Inrae,
NutriNeuro, U1286, University of Bordeaux, Bordeaux, France.
(6)French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN),
Saint-Germain-en-Laye, France; Fondation FondaMental, Créteil, France;
Department of Psychiatry, CHU of Clermont-Ferrand, University of Clermont
Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal (UMR 6602),
Clermont-Ferrand, France.
(7)French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN),
Saint-Germain-en-Laye, France; Clinique du Grand Pré, Durtol, France.
(8)French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN),
Saint-Germain-en-Laye, France; Fondation FondaMental, Créteil, France; Centre
d’investigation clinique, CIC-Inserm-1431, centre hospitalier universitaire de
Besançon, Besançon, France.
(9)French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN),
Saint-Germain-en-Laye, France; Fondation FondaMental, Créteil, France; UMR7289,
CNRS, pôle de psychiatrie, institut de neurosciences de la Timone, Aix-Marseille
université Assistance publique-Hôpitaux de Marseille, Marseille, France.
(10)French Society for Biological Psychiatry and Neuropsychopharmacology
(AFPBN), Saint-Germain-en-Laye, France; Fondation FondaMental, Créteil, France;
Department of Psychiatry, CHU of Clermont-Ferrand, University of Clermont
Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal (UMR 6602),
Clermont-Ferrand, France. Electronic address: .
INTRODUCTION: The purpose of this update is to add newly approved nomenclatures
and treatments as well as treatments yet to be approved in major depressive
disorder, thus expanding the discussions on the integration of resistance
factors into the clinical approach.
METHODS: Unlike the first consensus guidelines based on the RAND/UCLA
Appropriateness Method, the French Association for Biological Psychiatry and
Neuropsychopharmacology (AFPBN) developed an update of these guidelines for the
management of partially responsive depression (PRD) and treatment-resistant
depression (TRD). The expert guidelines combine scientific evidence and expert
clinicians’ opinions to produce recommendations for PRD and TRD.
RESULTS: The recommendations addressed three areas judged as essential for
updating the previous 2019 AFPBN guidelines for the management of patients with
TRD: (1) the identification of risk factors associated with TRD, (2) the
therapeutic management of patients with PRD and TRD, and (3) the indications,
the modalities of use and the monitoring of recent glutamate receptor modulating
agents (esketamine and ketamine).
CONCLUSION: These consensus-based guidelines make it possible to build bridges
between the available empirical literature and clinical practice, with a
highlight on the ‘real world’ of the clinical practice, supported by a pragmatic
approach centred on the experience of specialised prescribers in TRD.
Copyright © 2024 L’Encéphale, Paris. Published by Elsevier Masson SAS. All
rights reserved.
DOI: 10.1016/j.encep.2023.11.029
PMID: 38369426